Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 9/14/2014 11:54:40 AM - Followers: 191 - Board type: Free - Posts Today: 0



   
 



http://www.rexahn.com/cms/     

http://finance.yahoo.com/q/ks?s=RNN

About

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.
 

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.
 

Rexahn Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

PostSubject
#2739   Bouncing off the 50MA nicely, should see a srehmat02 09/10/14 01:54:02 PM
#2738   Bought in at .75 today, this chart looks srehmat02 09/10/14 01:45:53 PM
#2737   yep :) RNN Spuds McKenz66 09/09/14 10:17:51 AM
#2736   another solid day racamp101 09/05/14 09:22:16 AM
#2735   Those mini fractions at up when you trade Woulfe 09/04/14 04:08:07 PM
#2734   Can anyone answer y this trades in 4 ttubular 09/04/14 04:00:52 PM
#2733   Breakout?!?! Woot! JDV57 09/04/14 02:16:39 PM
#2732   This should make it back above a dollar soon. RookieStockPicker 09/04/14 08:10:06 AM
#2731   lots of volume. RNN Spuds McKenz66 09/03/14 11:35:20 AM
#2730   I don't know but I hope it spikes klbennie 09/03/14 10:40:06 AM
#2729   That could get really interesting if it is so! $tock Rev 09/03/14 10:39:53 AM
#2728   What's up with today spike ? Is a ttubular 09/03/14 10:13:43 AM
#2727   2.10 with a 3 to 1 Spuds McKenz66 08/27/14 11:51:17 AM
#2726   The Company is currently enrolling patients for its Spuds McKenz66 08/22/14 12:12:10 PM
#2725   AMEX and I agree ,asset managers sell 5 Spuds McKenz66 08/22/14 10:21:43 AM
#2724   cheap over sold , someone ones buying RNN Spuds McKenz66 08/22/14 10:20:04 AM
#2723   I don't see a reverse split happening until Woulfe 08/21/14 01:54:38 PM
#2722   Why do you feel this is buy time? klbennie 08/18/14 07:18:52 PM
#2721   buy time, load up RNN Spuds McKenz66 08/17/14 01:18:48 PM
#2720   Wish they would make a decision. The price klbennie 08/15/14 07:17:34 PM
#2719   Do you know when it's going to take effect? EPak 08/15/14 08:45:29 AM
#2718   To the best of my knowledge, they have thealias2002 08/15/14 06:46:59 AM
#2717   Been hearing for a while now but nothing definite. klbennie 08/15/14 12:56:42 AM
#2716   No idea nathan2123 08/15/14 12:40:13 AM
#2715   Any idea when this is happening? klbennie 08/15/14 12:25:38 AM
#2714   1 for every 5 shares or something nathan2123 08/14/14 11:41:47 PM
#2713   Do you know the ratio? EPak 08/14/14 11:09:01 PM
#2712   Reserve Split ?? Lol come This year Packardbell 08/05/14 08:59:02 AM
#2711   Hasn't this company put the Reverse Split into pineyhill 08/04/14 10:54:18 AM
#2710   $7 would be a heckofa Christmas present!! CJAKE1 08/01/14 04:31:17 PM
#2709   Here is a positive mention of RNN today: pmach64 07/31/14 06:18:01 PM
#2708   77 already RNN Spuds McKenz66 07/30/14 03:15:03 PM
#2707   http://ih.advfn.com/p.php?pid=nmona&article=62952284 Spuds McKenz66 07/30/14 12:38:43 PM
#2706   Wow!! Bold prediction!! CJAKE1 07/30/14 12:27:53 PM
#2705   RNN 7 bucks by xmas Spuds McKenz66 07/30/14 12:22:33 PM
#2704   back to a buck 80 , 1/3 split Spuds McKenz66 07/30/14 12:18:59 PM
#2703   Yes it does. My order at .70 did EPak 07/30/14 11:01:20 AM
#2702   I want able to buy at .70 and EPak 07/30/14 10:58:57 AM
#2701   looks good RNN :) Spuds McKenz66 07/30/14 10:57:58 AM
#2700   I just cancelled my order. I expected to EPak 07/29/14 10:20:48 AM
#2699   I don't think it's coming down to .70. EPak 07/29/14 09:58:37 AM
#2698   I've put order in. We will see if klbennie 07/29/14 09:50:00 AM
#2697   Don't feel bad we in same boat klbennie 07/29/14 09:44:42 AM
#2695   I too am going to better my position. klbennie 07/28/14 07:12:15 PM
#2694   I was in this stock at .84 and EPak 07/28/14 06:52:30 PM
#2693   OK, thanks. eventhelosers 07/28/14 11:27:38 AM
#2692   are you talking about revers split? mika7 07/28/14 11:26:17 AM
#2691   1for6 max maybe 1for3 will see Spuds McKenz66 07/28/14 10:51:33 AM
#2690   This talk of a split, fact or rumor? eventhelosers 07/27/14 09:41:50 AM
#2689   really, GO RNN GO Spuds McKenz66 07/23/14 09:20:18 AM
PostSubject